These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21487418)

  • 81. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.
    Fu Y; Zhuang Z
    Int J Clin Exp Pathol; 2014; 7(10):6419-29. PubMed ID: 25400720
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line.
    Badia E; Morena M; Lauret C; Boulahtouf A; Boulle N; Cavaillès V; Balaguer P; Cristol JP
    Breast Cancer; 2016 Sep; 23(5):692-700. PubMed ID: 26193841
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
    Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
    Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review.
    Monnier A
    Ther Clin Risk Manag; 2009 Oct; 5(5):725-38. PubMed ID: 19774214
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Risks and benefits of tamoxifen therapy.
    Assikis VJ; Jordan VC
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):21-3. PubMed ID: 9065923
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial.
    Gardner FJ; Konje JC; Bell SC; Abrams KR; Brown LJ; Taylor DJ; Habiba M
    Gynecol Oncol; 2009 Sep; 114(3):452-6. PubMed ID: 19576623
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer.
    Malek K; Fink AK; Thwin SS; Gurwitz J; Ganz PA; Silliman RA
    Med Care; 2004 Jul; 42(7):700-6. PubMed ID: 15213495
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Tamoxifen protects against steroid-induced bone loss.
    Fentiman IS; Saad Z; Caleffi M; Chaudary MA; Fogelman I
    Eur J Cancer; 1992; 28(2-3):684-5. PubMed ID: 1591093
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Prevention of Endometrial Cancer in Breast Cancer Patients Taking Tamoxifen : The Gynecologists' Role.
    Sinawat S
    Asian Pac J Cancer Prev; 2002; 3(3):251-255. PubMed ID: 12718583
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
    Henderson IC
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):31-4. PubMed ID: 15719599
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
    Henry NL; Rae JM; Li L; Azzouz F; Skaar TC; Desta Z; Sikora MJ; Philips S; Nguyen AT; Storniolo AM; Hayes DF; Flockhart DA; Stearns V;
    Breast Cancer Res Treat; 2009 Oct; 117(3):571-5. PubMed ID: 19153830
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Long-Term Follow-Up of the Intergroup Exemestane Study.
    Morden JP; Alvarez I; Bertelli G; Coates AS; Coleman R; Fallowfield L; Jassem J; Jones S; Kilburn L; Lønning PE; Ortmann O; Snowdon C; van de Velde C; Andersen J; Del Mastro L; Dodwell D; Holmberg S; Nicholas H; Paridaens R; Bliss JM; Coombes RC
    J Clin Oncol; 2017 Aug; 35(22):2507-2514. PubMed ID: 28467729
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.
    Love RR; Wiebe DA; Feyzi JM; Newcomb PA; Chappell RJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1534-9. PubMed ID: 7932809
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group.
    Baum M; Houghton J; Riley D
    Acta Oncol; 1992; 31(2):251-7. PubMed ID: 1622642
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Safety of aromatase inhibitors in the adjuvant setting.
    Perez EA
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Prevention: long-term benefits of tamoxifen.
    Hutchinson L
    Nat Rev Clin Oncol; 2011 Jun; 8(6):317. PubMed ID: 21487418
    [No Abstract]   [Full Text] [Related]  

  • 97. Safety and efficacy of antiestrogens for prevention of breast cancer.
    Reddy P; Chow MS
    Am J Health Syst Pharm; 2000 Jul; 57(14):1315-22; quiz 1323-5. PubMed ID: 10918921
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.
    Jordan VC
    Br J Pharmacol; 1993 Oct; 110(2):507-17. PubMed ID: 8242225
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Tamoxifen and related compounds protect against lipid peroxidation in isolated nuclei: relevance to the potential anticarcinogenic benefits of breast cancer prevention and therapy with tamoxifen?
    Wiseman H; Halliwell B
    Free Radic Biol Med; 1994 Nov; 17(5):485-8. PubMed ID: 7835756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.